NasdaqGM - Delayed Quote USD

Third Harmonic Bio, Inc. (THRD)

11.33 +0.28 (+2.53%)
At close: April 24 at 4:00 PM EDT
11.33 0.00 (0.00%)
After hours: April 24 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Natalie C. Holles CEO & Director 942.4k -- 1973
Mr. Steven P. Sweeney Senior Vice President of Development Operations -- -- --
Ommer Chohan Treasurer & Secretary -- -- --

Third Harmonic Bio, Inc.

1700 Montgomery Street
Suite 210
San Francisco, CA 94111
United States
(209) 727-2457 https://www.thirdharmonicbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
30

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Corporate Governance

Third Harmonic Bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

TYRA Tyra Biosciences, Inc.
16.00
-2.32%
 
AVTE Aerovate Therapeutics, Inc.
21.20
-8.70%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.97%
 
SYRE Spyre Therapeutics, Inc.
32.99
-3.68%
 
HLVX HilleVax, Inc.
12.58
-1.80%
 
CTNM Contineum Therapeutics, Inc.
15.93
+0.13%
 
FDMT 4D Molecular Therapeutics, Inc.
24.25
-2.26%
 
TNGX Tango Therapeutics, Inc.
7.76
-0.13%
 
KROS Keros Therapeutics, Inc.
56.24
+1.90%
 
TRVI Trevi Therapeutics, Inc.
2.6500
-7.02%